Histological findings after intralesional methotrexate treatment in cutaneous squamous cell carcinoma
Palabras clave : 
Intralesional methotrexate
Materias Investigacion::Ciencias de la Salud
Materias Investigacion::Ciencias de la Salud::Dermatología
Cutaneous squamous cell carcinoma (cSCC)
Keratoacanthoma (KA)
Fecha de publicación : 
2020
Editorial : 
Wiley
ISSN : 
1529-8019
Cita: 
Bergón-Sendín, M. (Marta); Parra-Blanco, V. (Verónica); Pulido-Pérez, A. (Ana); et al. "Histological findings after intralesional methotrexate treatment in cutaneous squamous cell carcinoma". Dermatologic Therapy. 33 (6), 2020, e14377
Resumen
Intralesional methotrexate (il-MTX) has been reported as a useful therapy in keratoacanthoma (KA) and cutaneous squamous cell carcinoma (cSCC). However, the data available on the histological changes induced by this therapy are very scarce. We conducted a single center, prospective study that included 65 cases of cSCC treated with il-MTX before surgical treatment. Two histological studies were conducted in all patients: before intralesional treatment and after surgical removal. Lesions were assessed longitudinally both clinically and histologically. 60 patients (92.3%) responded to il-MTX treatment. There were no differences regarding aggressive histological features of the cSCC between responder and non-responder patients. All cases showed a chronic inflammatory infiltrate after il-MTX. Intratumoral necrosis areas were frequently observed. All cases showed local fibrosis with fine thickening of collagen bundles. Il-MTX induces a chronic lymphohistiocytic inflammatory reaction in both clinical responder and nonresponder patients. Tumor involution after il-MTX is followed by a fine fibrosis that explains the great cosmetic results and improves the accuracy of the follow-up.

Ficheros en este ítem:
Vista previa
Fichero
Histological findings CE IL mtx.pdf
Descripción
Tamaño
3.36 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.